Quality‐of‐life analysis with intermittent vismodegib regimens in patients with multiple basal cell carcinomas: patient‐reported outcomes from the MIKIE study. (19th May 2020) - Schadendorf, D.; Hauschild, A.; Fosko, S.; Zloty, D.; Labeille, B.; Grob, J.‐J.; Puig, S.; Makrutzki, M.; Gilberg, F.; Hong, A.; Dréno, B.; Rogers, G.; et al.